4//SEC Filing
Oren Dan 4
Accession 0001104659-21-076488
CIK 0001006281other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 5:40 PM ET
Size
9.1 KB
Accession
0001104659-21-076488
Insider Transaction Report
Form 4
Dexcel Pharma Technologies Ltd.
10% Owner
Transactions
- Sale
Common Stock
2021-06-03$2.25/sh−857,506$1,932,304→ 3,637,314 total - Sale
Common Stock
2021-06-02$2.56/sh−61,211$156,553→ 4,494,820 total
Oren Dan
10% Owner
Transactions
- Sale
Common Stock
2021-06-02$2.56/sh−61,211$156,553→ 4,494,820 total - Sale
Common Stock
2021-06-03$2.25/sh−857,506$1,932,304→ 3,637,314 total
Footnotes (4)
- [F1]Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.
- [F2]The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive.
- [F3]The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive.
- [F4]The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001636701
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 5:40 PM ET
- Size
- 9.1 KB